Melinda Brown
Infectious Disease · New York, NYNPI 1942456272
Payments from drug & device makers
Across 286 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Viiv Healthcare Company$3K
- AbbVie$650
- Theratechnologies Inc.$308
- GSK$301
- Merck$288
- plus $935 from 11 others
What the payments were for
- Food & beverage$9,287100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 98 | $3,551 |
| Viiv Healthcare Company | 100 | $3,255 |
| AbbVie(2 entities) | 16 | $650 |
| Theratechnologies Inc. | 6 | $308 |
| GSK | 6 | $301 |
| Merck | 17 | $288 |
| Novo Nordisk | 8 | $212 |
| EMD Serono, Inc. | 10 | $192 |
| Exact Sciences | 5 | $143 |
| Pfizer | 4 | $64 |
| Lilly USA, LLC | 4 | $60 |
| Genentech USA, Inc. | 1 | $58 |
| Sanofi Pasteur Inc. | 3 | $51 |
| Napo Pharmaceuticals Inc | 2 | $51 |
| Phadia US Inc. | 3 | $50 |
| Boehringer Ingelheim | 2 | $29 |
| Hologic Sales And Service, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,287 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 36 | $27,364 |
| RybelsusSemaglutide | 13 | $19,768 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $14,198 |
| TrulicityDulaglutide | 12 | $11,526 |
| EliquisApixaban | 18 | $11,488 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,608 |
| Trueplus Pen NeedlePen Needle, Diabetic | 25 | $1,280 |
| Fluticasone Propionate | 19 | $318 |
| Gabapentin | 26 | $224 |
| Atorvastatin Calcium | 53 | $222 |
| Omeprazole | 13 | $164 |
| Ibuprofen | 11 | $163 |
| Carvedilol | 16 | $97 |
| Spironolactone | 13 | $81 |
| Amlodipine Besylate | 25 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29 | $27,36436 claims |
| Novo NordiskRybelsus | $212 | $19,76813 claims |
| MerckJanumet | $288 | $14,19823 claims |
| Lilly USA, LLCTrulicity | $60 | $11,52612 claims |
| PfizerEliquis | $64 | $11,48818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.
Other infectious disease in New York
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Thomas WalshNew York$1.4M
- Sean LiuNew York$1.4M
- Martin MarkowitzNew York$1.4M
- Angelica KottkampNew York$1.2M
- Michelle CespedesNew York$819K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.